The Talent Acquisition Week By GSMI is hosting three phenomenal events this week namely the Social Recruiting Strategies Conference, the Talent Sourcing Strategies Summit, and the Employer Branding Strategies Conference, in San Diego. Sourcers, recruiters, talent branders, HR managers & TA leaders, across industry verticals, are all invited to attend this comprehensive event connecting all recruiting sectors on the global spectrum. 

These events will feature panel discussions, case studies, and practitioner-to-practitioner sessions that attendees can leverage to gain in-depth knowledge about the latest recruiting industry trends, suitable candidates, tools and technology, and more. Learn the intricacies of recruitment marketing and tips to acquire the best industry talents to build a robust team. Attendees can connect and collaborate with the top TA & HR representatives and learn from their professional journeys. 

The Talent Acquisition Week 2024 offers:

• TA professionals can leverage networking opportunities to explore sourcing, employer branding, recruiting, and more
• Get insights, tips, and strategies from fellow TA practitioners for improving recruitment quality and candidate experiences
• Avail actionable tips and suggestions from eminent leaders conducting panel discussions and speaker sessions at the #TA Week 2024
• Learn the best employer branding techniques for building a great work team
• Get the best content tips to upgrade a company’s reputation
• Understanding the best criteria for hiring and sourcing the most suitable candidates

TA leaders and HR pros will host speaker sessions discussing the most vital topics of the recruitment arena and the best methods of recruitment and retention. This event offers the best platform for promising talent to be discovered. TA leaders can provide clear and effective recruitment information to an immersive audience. Fellow participants can develop long-term industry relations and get the best strategies for recruitment from fellow attendees.

To know more, please visit https://ibn.fm/hiA26

• SekurRelay allows business executives to benefit from Sekur’s privacy and security features seamlessly using their existing email while the rest of the employees maintain their existing hosting provider
• The service provides extra protection to senior employees and government officials against Business Email Compromise attacks
• Sekur plans to offer SekurRelay worldwide through telecom partners like America Movil in Latin America and new partners in the Middle East

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure and private communications, recently announced the launch of its SekurRelay Enterprise Email Solution. This new addition to Sekur’s existing suite of products allows corporate executives and management to “split” their company email domain in two without migrating the entire company of employees – eliminating a huge roadblock to mass adoption of SekurMail by large corporations and government entities (https://ibn.fm/xysyN).

SekurRelay simplifies the process for company employees to seamlessly transition their current business email to Sekur’s secure and private email platform while maintaining their existing business email domain, such as @company.com. This innovative solution eliminates the need for enterprise IT departments to undertake the complex and costly task of migrating their entire workforce to Sekur to maintain a consistent domain email address.

With SekurRelay, employees can continue using their current provider and email addresses like @company.com, while company executives and managers can enjoy the benefits of SekurMail with their existing email addresses. This “Inbound Relay” effectively addresses a significant challenge, as many larger enterprises have hesitated to migrate thousands of employee emails due to the associated complexities and expenses. With SekurRelay, companies of all sizes can safeguard the emails of C-level and management personnel from Business Email Compromise (“BEC”) attacks, all while allowing other employees to stay on their current email hosting providers.

All employee emails will pass through SekurRelay, benefiting from Sekur’s robust malware detection and spam filters, offering an extra layer of protection for everyone, regardless of whether they use SekurRelay. Only SekurRelay account holders will have their emails hosted and delivered through Sekur’s platform.

“We are excited to provide SekurRelay to our customers as it provides protection from BEC attacks to C-level executives and managers who traditionally send highly sensitive emails inside and outside of their organizations,” said Alain Ghiai, CEO of Sekur Private Data. Ghiai further explained that there were several instances when companies wanted to keep their existing email provider for convenience for most of their employees, but wanted to have their C levels use Sekur, while keeping the same company or government domain email.

Sekur can offer the only Swiss-hosted, proprietary, private, and secure communications platform that does not rely on big tech infrastructure, open-source coding, or data mining, therefore exponentially reducing the risk of cyber penetration. “Our prime directive is to provide private and secure communications for everyone, and as we are not connected to any Big Tech platform, we offer a truly independent, private, and secure means of communications, without any data mining, through our proprietary technology and our secure servers based in Switzerland,” Ghiai added.

The feature costs US$200/month per email domain plus an extra US$10/month per email for business accounts using SekurRelay. This totals US$20/month per business email, a minimal expense given SekurMail’s benefits and 100GB storage. For upcoming enterprise accounts in December 2023, the US$200/month domain add-on includes SekurRelay at a lower per-user rate due to a minimum of 50 users per account. SekurMail offers a unique SekurSend/SekurReply feature for secure communication. In 2021, there were 20,000 BEC attacks reported to the FBI.

Sekur plans to offer SekurRelay worldwide through telecom partners like America Movil in Latin America and new partners in the Middle East. This solution streamlines sales to larger businesses, enterprises, and government organizations without disrupting existing IT infrastructure or incurring migration costs, which is crucial in regions with increased cyber threats.

For more information, visit the company’s website at www.SekurPrivateData.com or the company’s product site at www.Sekur.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• Lexaria, a global innovator in drug delivery platforms, is projected by Zacks SCR to be valued at $10 a share, up from the current $1.50 for 2024
• Zacks SCR projects a 259% YOY revenue growth for 2024 and a 20% growth for 2025, dependent upon the ultimate approval and commercialization of products employing its patented DehydraTECH(TM) technology
• Lexaria also anticipates FDA approval for its IND application and commence its Phase 1b hypertension clinical trial, all in 2024

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has had significant developments in 2023. Most notably, the company has seen more positive results for its patented DehydraTECH(TM) technology for various indications, including potential diabetes treatment, oral nicotine, and hypertension. Results in these studies set the stage for additional clinical trials for 2024. These have contributed to the company’s projected valuation of $10 a share, up from the current $1.50, per a recent Zacks SCR report (https://ibn.fm/g4sZ8).

Zacks SCR projects 259% year-over-year (“YOY”) revenue growth for 2024 and a 20% YOY growth for 2025. This progression will largely depend on the ultimate approval and commercialization of products employing its DehydraTECH technology, mainly since the company receives most of its revenues from licensing and product sales, which can, in part, fund its research and development (“R&D”) operations. The success achieved so far in its hypertension, oral nicotine delivery, and diabetes studies shows important promise, and its management is optimistic that they will be integral to the company’s growth in the coming year.

In addition, other strategic moves that the company has made in 2023 are expected to further contribute to the company’s progress in 2024. Of note is the exclusive global collaboration and license agreement with SulfoSyn Limited that will allow for the non-pharmaceutical use of DehydraTECH with sulforaphane, a chemical compound found in a variety of cruciferous vegetables such as cabbage, cauliflower, and broccoli, among others. It is considered an antioxidant and anti-inflammatory with lots of health benefits. Another is Lexaria’s incorporation of a new wholly-owned subsidiary, Lexaria Nutraceutical Corp., that looks to optimize its DehydraTECH strategy that services several markets that fall under different regulatory regimes worldwide.

Within the first quarter of 2024, Lexaria anticipates approval for their Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its planned Phase 1b hypertension clinical trial, using DehydraTECH-CBD. It also hopes to close out its NIC-H22-1 clinical study on nicotine, update on final results, and commence with its Phase 1b hypertension study.  The company’s animal GLP-1 study is also set to begin, with an update on objectives scheduled for the year’s first half.

These initiatives reflect Lexaria’s commitment to creating shareholder value. They also indicate its management’s confidence in its technology. Lexaria has invested a lot of time and resources in the R&D for its technology since 2016, and it is about to pay off. With its unique benefits, which include, but are not limited to, increasing brain absorption, speeding up delivery, and increasing bioavailability, the technology is seeing a decent uptake, and with the plans lined up for 2024, it is bound to be even higher, ultimately stamping Lexaria as a leader in its space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• SOHM recently acquired ABBIE, a world-class gene-editing platform capable of inserting larger DNA sequences, including full genes, into a desired location of the target cell’s genome
• ABBIE is poised to facilitate drug development, with SOHM confident that its new gene-editing technology can revolutionize the field of cardiology by supporting new ways of discovering and developing drugs
• The ABBIE platform system is easy to operate and boasts high efficiency, low cost, and simple design
• ABBIE improves on some of the shortcomings of CRISPR-Cas9 as well as other gene-editing technologies, such as enabling researchers to edit genes of a large number of cell types at different stages of their life cycles and does not require the cutting of double stranded DNA
• Compared to other gene-editing technologies, ABBIE has achieved significant strides in development with much less R&D spending

Genome editing refers to the modification of a cell’s DNA (genome) to block, improve, restore or add gene expression and gene function. It may be used to modify genomic DNA of a cell or subject to correct or to provide a model for a genetic disease. The process alters the expression of the gene and corrects the mutations or genetic differences that cause disease, thus modulating the disease, for instance. Gene editing is the direct result of advancements in human genomics, clinical medicine, molecular biology, and genetics, which have made it possible to directly target and modify genomic sequences of cells with clearly defined nuclei (eukaryotic cells), including human cells (https://ibn.fm/UHi7v).

Over the years, researchers have developed new gene-editing platforms and technologies, one of which was recently acquired by SOHM (OTC: SHMN), a pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs. SOHM acquired ABBIE, a world-class gene-editing platform capable of inserting larger DNA sequences, including full genes, into a desired, predetermined, and precise location within the target cell’s genome (https://ibn.fm/ocohf). ABBIE uses non-viral vectors and engineered recombinant proteins combined with targeted integration to insert the DNA sequences.

SOHM’s new gene-editing technology, which is currently undergoing further development to optimize expression and purification of its protein-based platform, can facilitate drug discovery, essentially a process of finding new compounds that can regulate the function of a biological target, such as a gene involved in a disease, RNA, or a protein. SOHM believes ABBIE has the potential to transform and revolutionize the field of cardiology by supporting new ways of discovering and developing pertinent drugs.

According to SOHM COO Dr. David Aguilar, Ph.D., “ABBIE can facilitate drug discovery by allowing researchers to edit the DNA of cells in a dish (in vitro) and make them express a specific gene related to a cardiac disease. For example, ABBIE can be used to create cells that have a mutation in a gene that causes cardiomyopathy, a condition that adversely affects the heart muscle.”

Dr. Aguilar explains that these cells can then be exposed to various therapeutic compounds and subsequently screened to assess the impact such compounds have on the mutated cells as well as the cells’ function. In this way, he holds, ABBIE can help researchers identify new pharmacological candidates that can potentially treat or prevent conditions such as cardiomyopathy.

Moreover, ABBIE can enable researchers to edit the DNA of cells directly in the body (in vivo) and alter their behavior or activity. “For example, ABBIE can be used to target and modify the cardiac conduction cells of the heart, which are responsible for generating and transmitting electrical signals that coordinate the heartbeat. ABBIE can be used to correct or enhance the function of these cells in patients who have genetic conditions that affect their cardiac conduction system, such as long QT syndrome or Brugada syndrome,” continues Dr. Aguilar.

According to Dr. Aguilar, the development of the ABBIE system was inspired to improve the Clustered Regularly Interspaced Short Palindromic Repeats (“CRISPR”)-associated 9 (simply “CRISPR-Cas9”) gene-editing technology, which improved the speed and accessibility of gene editing to a larger number of laboratories. The CRISPR-Cas9 technology has generated plenty of excitement in the scientific community, becoming the most widely used gene editing tool compared to ZFN (zinc-finger nucleases) and TALENs (transcription activator-like effector nucleases), thanks in large part to its straightforward operation, high efficiency, low cost, and simple design (https://ibn.fm/9mPjB).

As a result, new genome editing systems, which are based on the CRISPR-Cas9 technology and/or are designed to deal with the shortcomings of this technology, provide higher efficiency of DNA insertion or recombination and increased targetability. ABBIE falls in the domain of new genome editing systems that improve on the CRISPR-Cas9 yet retain the high targetability of the technology’s Cas9 proteins. For instance, ABBIE is poised to be able to edit genes of a large number of cell types at different stages of their life cycles, overcoming the limitations of current cell editing and cell engineering systems. And compared to other gene-editing technologies, ABBIE has achieved the same level of progress with much less R&D spending.

SOHM has big plans for the ABBIE platform system. According to Dr. Aguilar, ABBIE will be utilized not only for human cell therapies but also for engineering plant DNA, potentially leading to increased generation of biofuels. The system can also be commercialized as a kit for off-the-shelf utility for clients such as universities, pharmaceutical industry companies, government laboratories, and private institutions. It can also deliver genes of interest for clinical trials.

For more information, visit the company’s website at www.SOHM.com.

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN

• A recent Reuters report focused its attention on rare earth mining companies’ efforts to strengthen American self-sufficiency in the production of natural elements vital to modern computerized products
• Rare earth element (“REE”) enterprise Ucore Rare Metals Inc. is gaining attention as a company focused on the refining of already mined rare earths to specialize in a particular sector of the supply chain, using its proprietary RapidSX(TM) technology
• The rare earth supply chain has been a subject of concern for years because of China’s near-monopoly on mining, refining, and production, for permanent magnets, strategic because of their use in a wide variety of applications, including electric vehicles and fighter jets
• The high value placed on strengthening rare earth supply chain independence is demonstrated in the multi-million dollar award Ucore has received from the U.S. Department of Defense, accompanied by a $4.28 million award from Canada, to advance its RapidSX(TM) commercialization

A range of concerns among government leaders and industry professionals have created a high-pressure competition to develop new REE refining solutions among Western enterprises. Issues that involve REE-based products include climate change, the mining industry’s forced reliance on Chinese companies for processing rare earth elements (“REEs”) used in modern computerized products, and also resource supply chain impediments sparked by the COVID pandemic and political sea changes.

Canadian-based Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is at the leading edge of the race, currently in the process of developing its Louisiana facility for the commercial-scale use of its proprietary RapidSX(TM) REE high-efficiency processing technology.

As evidence of the importance that REE processing capability presents in sustaining a wide variety of large-scale goals and policies, Ucore has benefitted from millions of dollars in project funding provided this year by U.S. and Canadian national government agencies (https://ibn.fm/Y1mFK).

“The existing rare earths refining process is a nightmare. … That’s why there are so many companies promising new methods, because we need new ones,” University of Arizona mining and geological engineering professor Isabel Barton told Reuters in a recent report on the REE refining race (https://ibn.fm/ouBPC).

The report noted that Ucore initially planned to mine a rare earths deposit in Alaska, where it has an effective 100 percent ownership stake, but that Ucore “changed tack” in 2022 to focus on refining after perceiving a flaw in the West’s strategy to weaken China’s minerals dominance by trying to master both mining and refining steps simultaneously.

Others who are involved in the industry appear to be following suit in their strategies. 

“Mining companies should focus on finding new deposits,” Luisa Moreno, the president of a Canadian REE mining company, told Reuters. “You probably should let refining be handled by others that specialize in that.” The company has expressed an interest in licensing Ucore’s technology, the report notes.

Ucore has spent the last several months demonstrating the capabilities of its RapidSX(TM) REE processing technology at a facility in Ontario, where it has conducted head-to-head comparisons between RapidSX(TM) and the industry-standard for REE solvent extraction (known as CSX, or simply SX).

The company’s preparations to launch commercial-scale operations at its Louisiana Strategic Metals Complex (“SMC”) facility — building up to 7,500 metric tons of total rare earth oxide (“TREO”) production from an initial 2,000 metric tons startup — is the first of three planned SMCs in the United States and Canada.

Ucore is in talks with 17 mining companies currently to buy their lightly processed supplies of rare earths and have them shipped to the Louisiana SMC for processing and eventual production of the permanent magnets key to computerized products ranging from uses in electric vehicles to U.S. fighter jets.

China’s decision in late November requiring government approval of its companies’ high-grade graphite exports, another element of the computerized products supply chain, focused additional attention on the industry trend because of concerns about Chinese authorities’ ability to pick and choose which companies will obtain Chinese graphite if they wish (https://ibn.fm/2kM60).

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• SuperCom, a leading provider of traditional and digital identity solutions, is offering advanced electronic monitoring solutions to address the growing cases of domestic violence worldwide
• Considering just the United States, domestic violence is now believed to affect 3 out of 10 women and 1 in 10 men
• With its PureProtect electronic monitoring technology, SuperCom is offering law enforcement near real-time information and many lines of communication, allowing for superior victim protection with the enforcement of court restrictions

SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions, offering advanced safety, identification, and security products and solutions to governments, is using advanced technology to reduce and prevent crime, specifically domestic violence. Through its propriety electronic monitoring (“EM”) platform, the company offers advanced EM solutions and services that have repeatedly been shown to protect domestic violence victims in multiple countries.

This comes in the wake of growing cases of domestic violence, a situation which is now encouraging governments to explore monitoring technology as a way to mitigate these cases. In England and Wales alone, a crime survey revealed that an estimated 2.1 million people aged 16 years and over experienced domestic abuse in the year ending March 2023. Police records showed a total of 889,918 domestic abuse-related crimes in the same period, a similar number to the previous year (https://ibn.fm/63hEe). In the United States, a study showed that nearly 3 in 10 women and 1 in 10 men had experienced rape, physical violence, and/or stalking by a partner, a worrying trend that calls for action sooner rather than later (https://ibn.fm/hQ328). By apprehending domestic violence offenders and then effectively monitoring them to prevent future contact with potential victims, cases of additional violence can be effectively prevented, something SuperCom’s EM technology is ideally designed to do.

In an FBI report released in 2022, it was noted that close to 600 murder-suicides occur yearly in the country, accounting for 1,000 to 1,500 deaths. Of the cases that law enforcement reports, 65% involve intimate partners, with 81% occurring in the home (https://ibn.fm/JxmPU). This is a worrying statistic, one that is further compounded by the fact that a domestic abuser is likely to abuse their partner again, even if previously incarcerated. A report showed that 10-18% of those arrested for domestic violence are arrested again in six months, while 15-30% face a second arrest within 28 months, and up to 60% are rearrested within ten years (https://ibn.fm/TP816).

To protect the victims of domestic abuse, governments are resorting to offender monitoring systems such as SuperCom’s. With its PureProtect product, the company can offer law enforcement near real-time information and many lines of communication, allowing for the enforcement of a safe distance between the offender and the victims. Its PureTag BLE bracelet with advanced tampering detection, paired with the PureMonitor software and PureProtect Smartphone, offers a life-saving domestic violence solution, allowing for victim protection and the enforcement of court restrictions (https://ibn.fm/a6i8M).

So far, several governments have adopted SuperCom’s offerings, recently including Romania and Finland. The company’s expansion into the US market promises to offer the same benefits, if not more, significantly enhancing the safety of domestic violence victims, particularly in the wake of the growing cases being reported. By doing so, the company is not only living up to its mission to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services but also to create shareholder value.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• SOHM, a generic drug manufacturing and distributing innovator, announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its ABBIE platform
• In the arrangement, SOHM will establish offices and a wet lab bench, taking advantage of UACI’s robust and specialized infrastructure
• SOHM’s management is optimistic about the collaboration and is confident that this is but the first step toward deepening new lab operations
• It also marks a significant milestone, as it anticipates monetizing ABBIE off-the-shelf, non-viral gene editing kits

SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, just announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its revolutionary ABBIE platform. This marks a significant milestone for SOHM, notably as it anticipates monetizing ABBIE off-the-shelf, non-viral gene editing kits through licensing opportunities as early as 2024 (https://ibn.fm/ZM4JH).

UACI expressed optimism in the arrangement, citing their confidence in ABBIE thriving through the program.

“We are delighted to assist SOHM and the development of ABBIE technology. UACI offers comprehensive support, including SBIR grant assistance, access to core research facilities, award opportunities, and investor networking,” noted Eric Smith, UACI’s Executive Director.

“Our Good Laboratory Practice (‘GLP’) facilities provide an ideal environment for technology growth, from conceptualization to clinical application. We are confident that ABBIE will thrive through our program,” he added.

In the arrangement, SOHM will establish offices and a wet lab bench, taking advantage of UACI’s robust and specialized infrastructure and a best-practice environment with certified GLP. It is confident that going with UACI would help fast-track development, ultimately allowing it to achieve its 2024 goal of taking the technology to market.

ABBIE, SOHM’s flagship offering, is a platform for non-viral gene editing technology that enables the rapid introduction of genes of interest while offering same-day screening. Given its potential, SOHM looks to develop and deploy non-viral gene-editing kits that will be developed into cell-based therapies, biologics, and diagnostics, ultimately allowing it to tap into the global biotechnology kit market, which is estimated to post a 10.9% CAGR between 2023 and 2030.

Industry experts have lauded non-viral gene-editing platforms, noting that they are at the forefront of research and development in genetics. In addition, they have highlighted their potential to treat genetic diseases while advancing biological research. More importantly, they have noted that non-viral gene-editing methods have shown potential in eliminating concerns related to immune responses, insertional mutagenesis associated with viral vectors, safety, and efficiency, as associated with current alternatives in the market.

SOHM’s management is optimistic about the collaboration and is confident that this is the first step toward deepening new lab operations.

“Having experienced the university’s world-class research facilities firsthand, I am confident in the success of ABBIE under this collaboration,” noted Dr. David Aguilar, SOHM’s COO.

“UACI has supported the company’s development. We recognize that this relationship will only deepen with the new lab operations,” he added.

For more information, visit the company’s website at www.SOHM.com.

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN

• As a European innovator with a worldwide outlook, Turbo Energy designs devices that showcase how AI can be applied to enhance everyday living with advanced software systems that monitor the generation, use, and management of photovoltaic energy
• Turbo Energy’s SunBox, or what the company calls one of the most advanced systems on the market, does not just aim to save power; it seeks to empower users with smart tools that help them make energy choices that suit their lifestyle
• Expanding beyond residential applications, Turbo Energy introduced commercial and industrial-scale solutions in 2023 and aims for a global footprint in fourteen countries

A decade ago, Turbo Energy (NASDAQ: TURB) surfaced as a company focused on disruptive photovoltaic energy technology. Its ambitious goal was to transform storage technology for off-grid residences. Now, integrated into a group boasting more than 20 years of industry experience, the company is unwaveringly committed to developing innovative photovoltaic management solutions tailored for residential, commercial, and industrial markets.

A device capable of connecting to everything—a lofty statement that, upon closer inspection of Turbo Energy’s SunBox Home technical details, appears to hold up. Marketed by the company as the most complete all-in-one device on the market, SunBox packs in inverters, batteries, and protective features, all rolled into one piece (https://ibn.fm/SbkM1).

While artificial intelligence (“AI”) applications continue to capture widespread attention across various facets of modern life and business, the application of AI in SunBox merits a closer examination. As users consume and generate photovoltaic (“PV”) power, the integrated AI system collects and analyzes this data along with weather information and energy prices. The goal is simple: manage household energy consumption efficiently and cost-effectively.

AI-powered SunBox Home seeks to put the power in users’ hands, offering a personalized experience with choices ranging from maximizing self-consumption to optimizing savings on electricity bills. In a climate where the financial strain on homeowners is palpable, AI-driven SunBox’s customizable modes aim to be more than a mere nod to energy efficiency; they seek to become a smart ally for homeowners navigating the challenges of rising living costs.

The flexibility extends to designating specific battery segments for blackout protection, with the AI seamlessly managing the intricate details. Users can also exercise control over energy delivery by selecting which storage section handles excess consumption.

In the face of increasingly unpredictable weather, SunBox Home steps up again to provide reassurance for homeowners. Its Activate smart storm protection system monitors the weather forecast, ensuring batteries are fully charged when storms are on the horizon.

After a decade dedicated to perfecting this innovative product tailored for the residential market, Turbo Energy appears to show no signs of slowing down. Building on its existing technical expertise, the company expanded into the EV segment in 2022, launching Sunbox with an integrated charger for electric vehicles. What seems to set Sunbox apart is its claim to fame as the only EV charger offering three charging modes along with its sophisticated AI algorithm, empowering homeowners to charge their vehicles directly with renewable energy at the lowest costs and highest speed.

But Turbo Energy’s growth trajectory appears to extend beyond product diversification; it also aims to encompass a strategic foray into new markets. Having solidified its position in Spain, the company embarked on a European expansion journey two years ago. Building on the success of its European growth, Turbo Energy now eyes expansion, with imminent operations launching in South America from its Chilean office (https://ibn.fm/VPOHP). The North American market is next on the agenda, with initial steps anticipated in 2024 (https://ibn.fm/eD2PB). According to its current expansion plans, Turbo Energy aims to extend its international footprint from nine to 14 countries, with the United States, Canada, Mexico, Chile, Peru, and Colombia featured as new spots on its international roadmap.

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

• Security tokens and tokenized securities are gaining attention as the drivers of evolution in companies’ investment platforms, but the two digital offerings have distinct qualities that explain their differing trajectories
• Tokenized securities’ links to specific off-chain assets and mimicry of established asset groups have thus far given them the advantage over the broader base of investment in security tokens that has attracted the attention of SEC regulation enforcers
• Utah-based Diamond Lake Minerals is building a portfolio of vertically integrated, industry-agnostic subsidiaries dedicated to regulatory compliance while opening doors to digital assets for traditional investors wary of digital assets
• DLMI’s strategy has led its market cap to grow exponentially from around $1 million to more than $100 million in about three months’ time, following years of relatively stagnant performance

The advent of tokenized assets and their upward spring in the marketplace is reflected in the rapid growth multi-strategy operating company Diamond Lake Minerals (OTC: DLMI) is experiencing in the wake of its reinvention from mining holding enterprise to the digital asset and security token space.

Tokenized securities have enjoyed a much less bumpy adoption trajectory than the somewhat analogous (but not entirely homologous) digital tokens that have been enjoying media attention because of U.S. Securities and Exchange Commission (“SEC”) enforcement actions against companies using tokens to fund their operations.

Security tokens are “blockchain-based representations of certain privileges such as revenue sharing, access, governance rights or a combination of these and others,” while tokenized securities are “tokens that represent either specific off-chain assets, or that mimic established asset groups such as bonds, shares or funds,” a CoinDesk article noted earlier this year (https://ibn.fm/gWWX4). “All tokenized securities could be classified as security tokens, but not all security tokens are tokenized securities. … The two concepts on the surface may appear similar but lift the lid and you can see that the difference is stark: It’s about clarity and establishment support versus the lack thereof.”

Diamond Lake Minerals is developing its operation by building a vertically integrated ecosystem of numerous industry-agnostic holdings and imbuing each with an SEC-registered security token offering (“STO”). The result is a portfolio of widely varied subsidiaries that will share resources and support one another while they’re growing and developing self-sufficiency, using STOs dedicated to each subsidiary as a means to attract traditional investors otherwise unfamiliar with digital assets but dependent on regulatory compliance.

Diamond Lake works with regulated SEC security token exchange partner INX to provide access to its companies before public trading commences. The INX Token was the first SEC-registered security token to IPO on the blockchain, and it relies on the checks and balances developed in traditional economic environs to provide a secure trading experience for all traders.

Diamond Lake’s market capitalization had held relatively steady at around $1 million for years, but following the introduction of experienced new management team members and advisers, as well as the rebrand to focus on digital assets during the past three months, DLMI’s cap has grown to over $100 million.

“I believe DLMI is the hybrid missing piece to get generational wealth, or the wealth on the sidelines,” CEO Brian J. Esposito said during a November Bell2Bell podcast interview (https://ibn.fm/0dej9).

“We’ll have media, we’ll have healthcare, … we’ll have music and IP, we’ll have the entertainment industry, we’ll have real estate opportunities,” Esposito said. “And (we’ll be) doing that in the correct fashion.”

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

In addition, for information on the company’s security token SEC regulated exchange partner INX, and the development of the INX Way, visit https://www.inx.co/inx-ebook/. This free security token bible, written with the SEC on the rollout of security tokens and the future of digital assets, will greatly deepen your understanding of security tokens.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• In November 2023, the company announced a purchase order from a Romanian company for seven TRACER 1000 ETDs to be deployed in a European airport
• Astrotech announced in June 2023 that its board unanimously rejected an unsolicited acquisition proposal from BML Investment Partners
• In May 2023, the company announced a purchase order from a Romanian company for 17 TRACER 1000 ETDs, to be delivered during calendar 2023
• Astrotech confirmed test results from field trials of the AgLAB 1000-D2 mass spectrometer for hemp and cannabis producers, improving yields by an average of 24%
• In December 2022, the company effected a 1-for-30 reverse stock split, reducing the number of outstanding common shares

Astrotech (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection.

The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing and mass spectrometer instrumentation units and adopted the Astrotech name.

In 2014, Astrotech sold its satellite subsidiary to focus on its Astrotech Technology Inc. (“ATi”) mass spectrometry solutions, which offer a number of advantages over competing platforms. Notably, Astrotech’s ATi technology is ruggedized, rapid, simple to use and customizable, with hands-free calibration and tuning.

Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (“ECAC”) certification for the TRACER 1000(TM), the world’s first mass-spec Explosives Trace Detector (“ETD”) used in airports worldwide. Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.

Astrotech is headquartered in Austin, Texas.

Subsidiaries

Astrotech Technologies Inc.

Astrotech Technologies Inc. (“ATi”) owns and licenses the platform mass spectrometry technology originally developed by 1st Detect. This technology is designed to be less expensive, smaller and easier to use than traditional mass spectrometers.

Unlike other technologies, ATi works under high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The company’s intellectual property includes 18 granted patents, along with extensive trade secrets.

ATi exclusively licenses the Astrotech Mass Spectrometer Technology to the three wholly owned subsidiaries of Astrotech.

1st Detect Corp.

1st Detect Corp. developed the TRACER 1000, the world’s first mass spectrometry-based explosives and narcotics trace detector. 1st Detect ETDs were developed for use at airports, cargo facilities and other secured locations and borders worldwide.

1st Detect’s commercial sales of the TRACER 1000 ETD, consumables and recurring maintenance services brought in $750,000 in total revenue during the fiscal year ended June 30, 2023. The Astrotech subsidiary recently secured two orders for a total of 24 Tracer 1000 units from two Romanian security and telecommunications companies, to be delivered during calendar 2023.

AgLAB Inc.

AgLAB Inc. is developing a series of mass spectrometers for use in the hemp and cannabis market, with an initial focus on optimizing yields in the distillation processes.

AgLAB, which uses the company’s proprietary AgLAB 1000-D2(TM) mass spectrometer, has been proven to improve distillation oil yields and bottom-line profits for hemp and cannabis producers. During field trials, AgLAB was able to improve ending-weight yields by an average of 24%.

BreathTech Corp.

BreathTech is developing the BreathTest-1000(TM), a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate they may have a compromised condition including but not limited to a bacterial or viral infection. The company believes that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present.

Market Opportunity

A report by Mordor Intelligence, a research and advisory firm, put the global mass spectrometry market at $6.37 billion in 2023. The market is forecast to grow to $8.63 billion by 2028, achieving a CAGR of 6.25% during the forecast period.

One of the major driving factors for the growth of the mass spectrometry market is technological advancements in mass spectrometer devices, the report states. Key market players are continuously working toward advancing their existing products and launching innovative and advanced mass spectrometer devices.

Another major factor that is expected to boost market growth is increasing research and development expenditure by both government and private entities, according to the report. Mass spectrometry devices are also being used in the detection and analysis of COVID-19 and other disease samples, which may have a positive impact on the market.

Management Team

The Astrotech leadership team includes management executives, as well as industry and technology experts. The company continues to actively expand its talent pool to meet evolving demands.

Thomas B. Pickens III is Chairman, CEO and Chief Technology Officer of Astrotech Corp. He also serves as CEO of Astrotech subsidiaries ATi, 1st Detect, AgLAB Inc. and BreathTech Corp. Previously, he was the founder and president of Beta Computer Systems Inc. and T.B. Pickens & Co. He was founder and general partner of Grace Pickens Acquisition Partners L.P and managing partner of Sumpter Partners. He also served as CEO of Catalyst Energy Corporation and United Thermal Corporation and as president of Golden Bear Corp., United Hydro Inc. and Slate Creek Corp. He received a B.A. in Economics, Computer Science and Engineering from Southern Methodist University.

Jaime Hinojosa, CPA, is CFO at Astrotech Corp. He joined the company in 2015 and has served as its Corporate Controller since 2019. His previous roles with the company include Director of Finance, from 2017 to 2019, and Assistant Controller, from 2015 to 2017. Prior to joining Astrotech, Mr. Hinojosa worked as an Accounting Manager for O’Reilly Auto Parts and gained public accounting experience as an Audit Manager at Burton McCumber & Cortez LLP.

For more information, visit the company’s website at www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC